NeurAxis, Inc. ( (NRXS) ) has released its Q1 earnings. Here is a breakdown of the information NeurAxis, Inc. presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
NeurAxis, Inc. is a medical device company based in Carmel, Indiana, specializing in the development and sale of neuromodulation devices for various medical conditions. In its latest earnings report for the quarter ended March 31, 2025, NeurAxis, Inc. reported net sales of $895,655, a significant increase from $646,635 in the same period last year. Despite the increase in sales, the company faced a net loss of $2,278,684, compared to a loss of $2,120,651 in the previous year, primarily due to higher general and administrative expenses. The company also reported a decrease in cash and cash equivalents from $3,696,870 at the end of 2024 to $2,005,370 as of March 31, 2025, reflecting the ongoing challenges in balancing operational costs with revenue generation. Looking ahead, NeurAxis, Inc. is focused on expanding its market presence and securing insurance coverage for its products, which is crucial for driving future revenue growth and achieving profitability.